1. Description
This is a targeted small-molecule pharmaceutical agent, formulated as oral film-coated tablets, with specified active ingredient content and standard pharmaceutical excipients (including microcrystalline cellulose, croscarmellose sodium, magnesium stearate etc.).
2. Indications
For the targeted treatment of corresponding mutation-positive malignant tumors (specific applicable tumor types need to be confirmed after clarifying the correct drug name).
3. Dosage and Administration
Oral administration, taken on an empty stomach 1 hour before meals or 2 hours after meals, do not chew or crush the tablets.
The standard recommended dose is determined according to the patient’s body weight, mutation status and disease stage, and must be prescribed by a professional oncologist.
4. Warnings and Precautions
Closely monitor the patient’s blood routine, liver and kidney function, and related targeted drug-specific adverse reaction indicators during the medication period.
5. Contraindications
Contraindicated in patients with confirmed hypersensitivity to the active ingredient or any excipients of the drug.
6. Adverse Reactions
Common adverse reactions include rash, diarrhea, fatigue, abnormal liver function, etc., and the specific incidence varies with the exact drug category.
7. Drug Interactions
Concomitant use of strong CYP3A4 inhibitors/inducers will affect the plasma concentration of the drug, and the medication plan needs to be adjusted by a doctor.
8. Use in Specific Populations
Contraindicated for pregnant and lactating women; pediatric and elderly patients need to adjust the dose under strict medical supervision.
Reviews
There are no reviews yet.